Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Tissue Repair Ltd ( (AU:TRP) ) just unveiled an announcement.
Tissue Repair Limited has initiated the Phase 3 clinical trial for its lead product, TR987®, involving 600 participants to confirm its efficacy in treating venous leg ulcers. This trial, conducted across major hospitals in Australia and the US, marks a critical step in the company’s mission to provide a cost-effective, advanced treatment for chronic wounds, potentially positioning TR987® as a leading therapy in a market burdened by significant healthcare costs and patient quality of life challenges.
More about Tissue Repair Ltd
Tissue Repair Limited operates in the chronic wound care industry, focusing on innovative treatments for chronic, non-healing wounds. The company’s primary product, TR987®, is a proprietary B-D glucan molecule developed in Australia, aimed at improving healing outcomes in chronic wounds, particularly venous leg ulcers, in response to increasing incidences driven by factors like an ageing population, obesity, and diabetes.
YTD Price Performance: -1.79%
Average Trading Volume: 35,847
Technical Sentiment Consensus Rating: Buy
For an in-depth examination of TRP stock, go to TipRanks’ Stock Analysis page.
